Previous pharmaco-rsfMRI studies have demonstrated that intranasal OXT modulates the connectivity of the amygdala with prefrontal regions (Dodhia et al., 2014; Koch et al., 2016; Eckstein et al., 2017; Jiang et al., 2021) and the hippocampus (Fan et al., 2015; Kirkby et al., 2018; Alaerts et al., 2019), while animal models and an initial human study suggest that some effects of OXT in the domains of anxiety and amygdala threat reactivity are critically mediated by the 5-HT system (Yoshida et al., 2009; Mottolese et al., 2014). The gene discussed is OXT; the disease is Anxiety.